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Background and Purpose  The associations between hearing loss (HL) and the mechanisms 
underlying cognitive impairment (CI) remain unclear. We evaluated the effects of clinical 
factors, vascular magnetic resonance imaging (MRI) markers, and CI mechanisms on HL.
Methods  In total, 112 patients with CI (59% demented) and subjective HL prospectively un-
derwent MRI, amyloid positron-emission tomography (PET), hearing evaluations, and neu-
ropsychological tests including a language comprehension test. Patients were categorized into 
pure-Alzheimer’s disease-related CI (ADCI), pure-Lewy-body disease-related CI (LBCI), 
mixed-ADCI/LBCI, and non-ADCI/LBCI groups based on clinical features and PET bio-
markers.
Results  The risk of peripheral HL [defined as a pure-tone average (PTA) threshold >40 dB] 
was higher in the pure-LBCI group than in the pure-ADCI and mixed-ADCI/LBCI groups, 
and lower in the presence of ADCI. The non-ADCI/LBCI group had the most-severe vascu-
lar MRI markers and showed a higher risk of peripheral HL than did the pure-ADCI and 
mixed-ADCI/LBCI groups. While the pure-LBCI group had a higher risk of comprehension 
dysfunction than the pure-ADCI group regardless of the PTA and the score on the Korean 
version of the Mini Mental State Examination (K-MMSE), those in the pure-LBCI group 
even with a better K-MMSE score had a risk of comprehension dysfunction comparable to 
that in the mixed-ADCI/LBCI group due to a worse PTA.
Conclusions  Peripheral HL could be associated with the absence of significant β-amyloid de-
position in patients with CI and characteristic of the pure-LBCI and non-ADCI/LBCI groups.
Key Words   hearing loss, Alzheimer’s disease, Lewy body disease, Parkinson’s disease, 
vascular dementia, cognitive impairments.
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INTRODUCTION
Hearing loss (HL) and cognitive dysfunction are prevalent in older adults. Both cross-sec-
tional1,2 and longitudinal3-6 studies have shown that peripheral HL is associated with cog-
nitive dysfunction and dementia, but this is still controversial7-9 due to the underlying mech-
anism being elusive. Dementia has multiple causes, including Alzheimer’s disease (AD), 
Lewy-body disease (LBD), and vascular cognitive impairment (CI),10 and so the type of de-
mentia must be considered when attempting to elucidate the exact mechanisms underly-
ing the association between HL and dementia.
Previous studies have suggested potential mechanisms for explaining this association. 
First, older age, microvascular pathology, and vascular risk factors may give a spurious ap-
pearance of a connection, since these parameters are all associated with both cognitive dys-
function and HL (the common-cause hypothesis).11 Second, the cognitive overload caused 
by effortful listening (the cognitive-load hypothesis) or the impoverished sensory input 
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caused by HL (the cascade hypothesis) may accelerate neu-
rodegenerative changes.12
Based on previous studies showing a close relationship be-
tween HL and dementia with diverse etiologies,1-6 we hypoth-
esized that HL is affected differently depending on the causes 
of CI and dementia, underpinning the common-cause hy-
pothesis. In this study we assessed the degree of HL using the 
pure-tone average (PTA) in pure-tone audiometry, and the 
word recognition score (WRS) in speech audiometry. The 
relationship between HL and the mechanisms underlying CI 




Between May 2016 and October 2018, consecutive patients 
complaining of cognitive dysfunction were prospectively en-
rolled from a university-based memory clinic. Written in-
formed consent was obtained from all participants. All of the 
included patients underwent hearing evaluations, neuropsy-
chological tests, brain structural magnetic resonance imag-
ing (MRI), and 18F-fluorodeoxyglucose (FDG) positron-
emission tomography (PET). 18F-florbetaben (FBB) PET was 
performed to confirm cerebral β-amyloid deposition in all 
patients, and 18F-N-(3-fluoropropyl)-2β-carboxymethoxy-
3β-(4-iodophenyl) nortropane (FP-CIT) PET was performed 
to confirm dopamine depletion based on clinical needs. This 
prospective study was approved by the Institutional Review 
Board of Yonsei University Medical College (IRB No. 4-2016-
0648). 
The following exclusion criteria were applied: 1) conduc-
tive HL in pure-tone audiometry; 2) HL related to congeni-
tal, traumatic, or infective causes; or 3) other causes of cog-
nitive dysfunction including normal-pressure hydrocephalus, 
traumatic encephalopathy, large-territory cerebral infarction, 
acute or subacute cerebral infarction or hemorrhage, fronto-
temporal lobar degeneration, or atypical parkinsonism in-
cluding progressive supranuclear palsy, multiple-system atro-
phy, and corticobasal degeneration. This study enrolled 112 
patients who underwent a clinical interview, neurological ex-
aminations, and laboratory tests including a complete blood 
count, blood chemistry, vitamin B12, folate, thiamine, syph-
ilis serology, thyroid function, and apolipoprotein E (APOE) 
genotyping. 
Diagnosis and categorization of patients 
Because AD and LBD are the two most common degenera-
tive causes of dementia, and vascular disease frequently co-
occurs in the elderly,13-15 the participants in the present study 
were categorized into pure-AD-related CI (ADCI), pure-LBD-
related CI (LBCI), mixed-ADCI/LBCI, and non-ADCI/LBCI 
groups. The severity of vascular disease was measured using 
the modified Fazeka’s scale (see MRI scan acquisition and 
interpretation section). ADCI included AD dementia and 
mild CI (MCI) due to AD. Clinical AD dementia was diag-
nosed according to the criteria of the National Institute of 
Neurological and Communicative Disorders and Stroke and 
the Alzheimer’s Disease and Related Disorders Association 
(NINCDS-ADRDA).16 MCI due to AD was diagnosed based 
on modified Petersen’s criteria.17 LBCI included Parkinson’s 
disease (PD) dementia, MCI due to PD, dementia with Lewy 
bodies (DLB), and MCI due to DLB. The United Kingdom 
Parkinson’s Disease Society Brain Bank diagnostic criteria for 
PD were used to diagnose PD,18 and all patients with DLB 
met the criteria for probable DLB.19
All study participants underwent FDG PET and 18F-FBB 
PET [Acquisition and interpretation of FBB, FP-CIT, and FDG 
PET (with CT) scans section], and they were categorized into 
ADCI and non-ADCI groups based on the 18F-FBB PET re-
sults. If participants had a score on the Unified Parkinson’s 
Disease Rating Scale of >16, they were regarded as having 
significant parkinsonism. Participants with more than two 
symptoms among cognitive fluctuation, visual hallucination, 
and parkinsonism were regarded as having DLB. DLB pa-
tients and participants with significant parkinsonism and ni-
grostriatal dopamine depletion on 18F-FP-CIT PET were re-
garded as having LBCI. 
The study participants were categorized into 19 patients 
with pure ADCI, 38 with pure LBCI, 45 with mixed ADCI/
LBCI, and 10 with non-ADCI/LBCI, among whom signifi-
cant parkinsonism was present in 7, 37, 42, and 9, respective-
ly. Ten DLB patients did not undergo 18F-FP-CIT PET, two of 
whom did not have significant parkinsonism. All DLB pa-
tients had characteristic FDG metabolic increases in the pos-
terior putamen, somatomotor cortex, and vermis.20 All 7 
pure-ADCI and 10 non-ADCI/LBCI patients who had sig-
nificant parkinsonism underwent 18F-FP-CIT PET, and they 
did not exhibit nigrostriatal dopamine depletion.
Neuropsychological evaluation
A standardized neuropsychological battery [the Seoul Neu-
ropsychological Screening Battery (SNSB)] was performed as 
we have described previously.21,22 The SNSB includes scorable 
and nonscorable tests in the attention, memory, visuospatial, 
language, and frontal/executive domains. General cognitive 
function was assessed using the Korean version of the Mini 
Mental State Examination (K-MMSE). Language-related func-
tion was dichotomized into normal and abnormal based on 
the spontaneous speech fluency, comprehension function (as-
292  J Clin Neurol 2021;17(2):290-299
Hearing Loss According to Dementia Type JCN
sessed by asking five yes/no questions), repetition of five sen-
tences, writing ability, finger-naming test, right-left orienta-
tion test, body-part identification test, and buccofacial praxis 
test. The severity of depressive symptoms was assessed using 
the Beck Depression Inventory (BDI).
MRI scan acquisition and interpretation
All MRI scans were acquired using a 3-T scanner (Philips 
Intera, Philips Medical Systems, Best, The Netherlands). We 
have described the MRI methodology in detail previously.22 
Structural abnormalities including territorial cerebral in-
farction, acute or subacute cerebral infarction or hemorrhage, 
and normal-pressure hydrocephalus were identified for ap-
plying the study exclusion criteria.
The severity of subcortical vascular changes on MRI was 
measured by applying the modified Fazeka’s scale to white-
matter hyperintensities (WMHs) and manually counting lacu-
nes and cerebral microbleeds (CMBs). Periventricular WMHs 
were classified into P1 (cap and band <5 mm), P2 (5 mm≤ 
cap or band <10 mm), and P3 (cap or band ≥10 mm). Deep 
WMHs were classified as D1 (maximum diameter of deep 
white-matter lesion <10 mm), D2 (10 mm≤ lesion <25 mm), 
and D3 (lesion ≥25 mm). Lacunes were defined as small le-
sions (≥3 mm and ≤15 mm in diameter) with high signals 
on T2-weighted images, low signals on T1-weighted images, 
and a perilesional halo on FLAIR images. CMBs were de-
fined as round lesions (<10 mm in diameter) with homoge-
neous low signal intensities on T2*-weighted gradient recalled-
echo images. WMHs, lacunes, and CMBs were rated by a 
neurologist (B.S.Y.).
Acquisition and interpretation of FBB, FP-CIT, and 
FDG PET (with CT) scans
FP-CIT PET, FDG PET, and FBB PET scans were acquired 
using a Discovery 600 device (GE Healthcare, Milwaukee, 
WI, USA). We have described the acquisition and reconstruc-
tion protocols for FP-CIT and FBB PET previously.23 FDG 
PET scans were acquired for 15 minutes at 60 minutes after 
intravenously injecting FDG at approximately 4.1 MBq/kg 
(body weight). Spiral computed tomography scanning for at-
tenuation correction was performed with the following pa-
rameters: 0.8-second rotation time, 60 mA, 120 kVp, 3.75-
mm section thickness, 0.625-mm collimation, and 9.375-mm 
table feed per rotation. An expert in nuclear medicine (M.J.Y.) 
and a neurologist with expertise in dementia (B.S.Y.) per-
formed visual ratings of the brain β-amyloid plaque load 
(BAPL) score and FP-CIT PET abnormalities. BAPL scores 
of 2 and 3 were regarded as β-amyloid positive, while BAPL 
scores of 1 were considered β-amyloid negative. 
Hearing evaluation
Audiological evaluations, including pure-tone audiometry 
and speech audiometry, were performed when patients first 
visited after their enrollment. The pure-tone air conduction 
(250–8,000 Hz) and bone conduction (250–8,000 Hz) thresh-
olds were measured using clinical audiometers in a double-
walled audio booth. The mean PTA thresholds for air conduc-
tion at 500, 1,000, 2,000, and 4,000 Hz (PTA4) were determined. 
The air-conduction PTA threshold of the better ear was used 
in this study, since hearing ability is mainly determined by the 
better ear. PTA-based HL was defined as PTA4 >40 dB HL. 
Speech audiometry was performed to obtain the WRS, which 
was measured at the most comfortable hearing level using 
50 monosyllabic Korean words that are heard during every-
day life. These words were obtained from a validated and stan-
dardized resource and were phonetically balanced. WRS-
based HL was defined as WRS <70%.
Statistical analyses
All statistical analyses were performed using SPSS software 
(version 23.0; IBM Corp., Armonk, NY, USA). Student’s t-
test and analysis of variance were used to compare continuous 
variables, while chi-square tests were used to compare cate-
gorical variables. General linear models were used to identify 
associations between hearing indices and various factors in-
cluding age, sex, education level, carrying the E4 variant of the 
APOE gene (APOE4), BDI score, K-MMSE score, cognitive 
status (demented vs. nondemented), ADCI diagnosis, LBCI 
diagnosis, disease group (classified into pure ADCI, pure 
LBCI, mixed ADCI/LBCI, and non-ADCI/LBCI), and MRI 
vascular markers including deep WMHs, periventricular 
WMHs, lacunes, and CMBs. 
Logistic regression analyses were performed to identify the 
associations of the various factors with the risk of HL. To 
identify significant covariates, univariate analyses were per-
formed after controlling for age, sex, and education level (Sup-
plementary Tables 1 and 2 in the online-only Data Supple-
ment). Variables that showed univariate associations with 
p<0.05 as covariates were then included in multivariate anal-
yses of the associations of HL with the diagnosis, using the 
presence of ADCI and LBCI (Model 1) or the disease group 
(Model 2) as predictors (Tables 2 and 3). 
Comprehension dysfunction was significantly associated 
with the PTA and WRS (Supplementary Table 1 in the on-
line-only Data Supplement). However, since comprehension 
dysfunction could be the result of HL rather than the cause, 
we did not include it as a predictor in the multivariate mod-
els. Because peripheral HL can impair comprehension func-
tion, logistic regression analyses were performed to evalu-
ate whether the risk of comprehension dysfunction differed 
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according to the disease group. Variables showing significant 
associations (p<0.05) in univariate logistic regression analy-
ses of comprehension dysfunction after controlling for age, 
sex, and education level were selected (Supplementary Ta-
ble 3 in the online-only Data Supplement) for inclusion in 
multivariate logistic regression analyses. To test whether the 
risk of comprehension dysfunction was influenced by pe-
ripheral HL and general cognition, logistic regression anal-
yses were performed while removing the PTA and both the 
PTA and K-MMSE score, respectively.
RESULTS
Demographic and clinical characteristics
There were no significant intergroup differences in age, ed-
ucation level, BDI score, vascular risk factors including hy-
pertension, diabetes mellitus, dyslipidemia, and smoking, or 
MRI vascular markers including deep WMHs, periventric-
ular WMHs, and CMBs (Table 1). There were more lacunes 
in the non-ADCI/LBCI group than in the pure-ADCI, pure-
LBCI, and mixed-ADCI/LBCI groups. The proportion of 
APOE4 carriers was higher in the pure-ADCI and mixed-
Table 1. Demographic characteristics of the study participants
Pure ADCI (n=19) Pure LBCI (n=38) Mixed ADCI/LBCI (n=45) Non-ADCI/LBCI (n=10) p
Age, years 74.6±7.5 78.7±6.5 76.8±6.0 75.4±4.0 0.119
Sex, female 13 (68.4) 23 (60.5) 29 (64.4) 4 (40.0) 0.472
Education level, years 8.2±5.5 8.8±5.2 9.2±4.9 8.0±5.6 0.878
Duration of CI, years 2.3±1.3 2.6±1.6 2.7±2.2 2.4±1.6 0.831
Duration of parkinsonism, years 2.9±2.0 2.0±1.8 1.9±2.4 1.6±1.5 0.622
Significant parkinsonism  
  (UPDRS score >16)
7 37 42 9 <0.001*
Vascular risk factors
Hypertension 13 (68.4) 24 (63.2) 27 (60.0) 7 (70.0) 0.892
Diabetes mellitus 3 (15.8) 15 (39.5) 11 (24.4) 2 (20.0) 0.211
Dyslipidemia 3 (15.8) 8 (21.1) 8 (17.8) 4 (40.0) 0.424
Smoking 5 (26.3) 8 (21.1) 10 (22.2) 3 (30.0) 0.922
MRI vascular markers
Deep WMHs 1.8±0.7 1.8±0.6 1.5±0.6 2.0±0.6 0.157
Periventricular WMHs 1.8±0.7 2.1±0.7 1.9±0.8 2.4±1.0 0.133
Lacunes 3.3±4.4c 2.6±4.7e 1.5±2.1f 6.9±6.8c,e,f 0.003
CMBs 2.2±5.3 1.5±3.4 0.7±1.5 6.3±18.2 0.079
Carrier of APOE4 allele 10 (43.5)a,c 6 (15.0)a,d 26 (50.0)d,f 1 (10.0)c,f 0.001*
Cognitive status 0.002*
Nondemented 12 (63.2) 16 (42.1) 11 (24.4) 8 (80.0)
Demented 7 (36.8)b 22 (57.9)e 34 (75.6)b,f 2 (20.0)e,f
Hearing indices
PTA, dB HL 34.3±11.7a 47.8±17.1a,d 32.8±15.5d,f 45.6±8.4f <0.001*
WRS 79.6±18.0a 62.8±26.5a,d 80.3±18.1d 72.2±19.3 0.002*
PTA-based HL 4 (21.1)a,c 27 (71.1)a,d 16 (35.6)d,f 8 (80.0)c,f <0.001*
WRS-based HL 3 (15.8) 18 (47.4) 11 (24.4) 3 (30.0) 0.053
BDI score 11.4±9.1 14.3±10.3 12.4±8.9 12.0±9.0 0.687
K-MMSE score 23.3±4.2b 23.2±4.0d 20.4±5.1b,d,f 24.0±4.5f 0.013*
Comprehension dysfunction 1 (5.6)a 15 (41.7)a 10 (23.8) 2 (20.0) 0.034*
PTA-based HL was defined as PTA4 >40 dB HL and WRS-based HL was defined as WRS <70%. Data are mean±SD or n (%) values. MRI vascular mark-
ers refer to the modified Fazeka’s scale to WMHs. Group comparisons were performed using chi-square tests or analyses of variance as appropriate. 
*p<0.05, aSignificant difference between pure-ADCI and pure-LBCI groups, bSignificant difference between pure-ADCI and mixed-ADCI/LBCI groups, 
cSignificant difference between pure-ADCI and non-ADCI/LBCI groups, dSignificant difference between pure-LBCI and mixed-ADCI/LBCI groups, eSig-
nificant difference between pure-LBCI and non-ADCI/LBCI groups, fSignificant difference between mixed-ADCI/LBCI and non-ADCI/LBCI groups.
ADCI: Alzheimer’s disease-related cognitive impairment, APOE4: apolipoprotein E gene E4 variant, BDI: Beck Depression Inventory, CI: cognitive im-
pairment, CMBs: cerebral microbleeds, HL: hearing loss, K-MMSE: Korean version of the Mini-Mental State Examination, LBCI: Lewy-body disease-re-
lated cognitive impairment, MRI: magnetic resonance imaging, PTA: pure-tone average, WMHs: white-matter hyperintensities, WRS: word recogni-
tion score.
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ADCI/LBCI groups than in the pure-LBCI and non-ADCI/
LBCI groups. The proportion of demented patients was high-
er in the mixed-ADCI/LBCI group than in the pure-ADCI 
and non-ADCI/LBCI groups. The proportion of demented 
patients was higher in the pure-LBCI group than in the non-
ADCI/LBCI group. The K-MMSE score was lower in the 
mixed-ADCI/LBCI group than in the pure-ADCI, pure-LB-
CI, and non-ADCI/LBCI groups. The pure-LBCI group had 
a higher PTA and lower WRS compared with the pure-ADCI 
and mixed-ADCI/LBCI groups. The PTA was higher in the 
non-ADCI/LBCI group than in the pure-ADCI and mixed-
ADCI/LBCI groups (Table 1, Fig. 1).
Univariate associations of clinical and imaging 
factors with auditory function
Univariate general linear models obtained after controlling 
for age, sex, and education level showed that a higher PTA 
was associated with APOE4 negativity, higher K-MMSE score, 
the presence of comprehension dysfunction, and the absence 
of ADCI (Supplementary Table 1 in the online-only Data Sup-
plement). A lower WRS was associated with more CMBs, 
higher BDI score, the presence of comprehension dysfunc-
tion, and the absence of ADCI. The pure-LBCI group had a 
higher PTA and lower WRS compared with the pure-ADCI 
and mixed-ADCI/LBCI groups. 
Univariate logistic regression analyses performed after con-
trolling for age, sex, and education level showed that PTA-
based HL (PTA4 >40 dB) was associated with more-severe 
periventricular WMHs and the absence of ADCI. WRS-based 
HL (WRS <70%) was associated with the absence of smok-
ing and the absence of ADCI (Supplementary Table 2 in the 
online-only Data Supplement). The odds ratio (OR) for PTA-
based HL was higher for the pure-LBCI group than for the 
pure-ADCI and mixed-ADCI/LBCI groups. However, the 
four disease groups had comparable ORs for WRS-based HL. 
Multivariate associations of clinical and imaging 
factors with auditory function
A multivariate general linear model for the PTA showed that 
a higher PTA was associated with older age and the absence 
of ADCI, while sex, education level, lacunes, APOE4 positiv-
ity, and the presence of LBCI were not associated with the 
PTA (Table 2). After controlling for age, sex, education level, 
and APOE4 positivity, the PTA was higher in the pure-LBCI 
group than in the pure-ADCI and mixed-ADCI/LBCI groups. 
A multivariate general linear model for the WRS showed that 
a lower WRS was associated with more CMBs, higher BDI 
score, and the absence of ADCI, while age, sex, education lev-
el, and the presence of LBCI were not associated with the 
WRS. After controlling for possible confounders, the WRS 
was lower in the pure-LBCI group than in the pure-ADCI 
and mixed-ADCI/LBCI groups.
A multivariate logistic regression analysis of PTA-based HL 
showed that older age and the absence of ADCI were inde-
pendently associated with a higher OR for PTA-based HL, 
while sex, education level, periventricular WMHs, and the 
presence of LBCI were not (Table 3). After controlling for 
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500 201,000 402,000 604,000 808,000 100
Fig. 1. Audiological results in patients compared with cognitive dysfunction and subjective hearing impairment. A: Pure-tone audiograms of 112 
patients (both ears) are plotted according to the mechanisms underlying cognitive dysfunction. B: The PTA and WRS are plotted. PTA-based HL 
was defined as PTA4 (average of thresholds at 500, 1,000, 2,000, and 4,000 Hz) >40 dB HL, and WRS-based HL was defined as WRS <70% (red and 
blue dotted lines, respectively). ADCI: Alzheimer’s disease-related cognitive impairment, HL: hearing loss, LBCI: Lewy-body disease-related cognitive 
impairment, PTA: pure-tone average, WRS: word recognition score.
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er in the pure-LBCI and non-ADCI/LBCI groups than in 
the pure-ADCI and mixed-ADCI/LBCI groups. A multivari-
ate logistic regression analysis of WRS-based HL showed that 
older age, male sex, and the absence of smoking were inde-
pendently associated with a higher OR for WRS-based HL, 
while education level, the presence of ADCI, and the presence 
of LBCI were not. After controlling for possible confound-
ers, there was no significant difference in the OR for WRS-
Table 3. Association of clinical factors and diagnosis with the presence of hearing impairment
PTA-based HL WRS-based HL
Model 1 p Model 2 p Model 1 p Model 2 p
Age, years 1.15 (1.05–1.25) 0.002* 1.15 (1.06–1.26) 0.001* 1.12 (1.02–1.22) 0.013 1.12 (1.02–1.22) 0.013*
Sex, male 1.56 (0.57–4.28) 0.387 1.46 (0.53–4.02) 0.467 4.24 (1.20–15.00) 0.025 4.42 (1.23–15.93) 0.023*
Education level, years 0.94 (0.85–1.04) 0.244 0.94 (0.85–1.04) 0.246 0.93 (0.84–1.02) 0.135 0.93 (0.84–1.03) 0.146
Periventricular WMHs 1.55 (0.86–2.82) 0.147 1.55 (0.85–2.85) 0.154
Smoking 0.24 (0.06–0.96) 0.043 0.23 (0.06–0.91) 0.037*
ADCI diagnosis 0.19 (0.07–0.46) <0.001* 0.44 (0.18–1.06) 0.068
LBCI diagnosis 1.35 (0.48–3.83) 0.568 2.11 (0.66–6.78) 0.208
Disease group
Pure ADCI 0.13 (0.03–0.53) 0.005* 0.28 (0.06–1.22) 0.089
Pure LBCI Reference Reference
Mixed ADCI/LBCI 0.25 (0.09–0.70) 0.008* 0.42 (0.16–1.15) 0.092
Non-ADCI/LBCI 2.22 (0.34–14.66)† 0.407 0.52 (0.10–2.63) 0.427
Data are OR (95% CI) values. Data are results of logistic regression analyses of the presence of hearing impairment using age, sex, education level, 
and factors that showed significant associations with HL based on each hearing index in Supplementary Table 2 as covariates. Model 1 used the pres-
ence of ADCI and LBCI as predictors. Model 2 used disease group as a predictor. PTA-based HL was defined as PTA4 >40 dB HL and WRS-based HL was 
defined as WRS <70%. p values in the Hosmer and Lemeshow test for PTA model 1, PTA model 2, WRS model 1, and WRS model 2 were 0.890, 0.279, 
0.691, and 0.419, respectively. 
*p<0.05, †The OR for PTA-based HL was significantly higher in the non-ADCI/LBCI group than in the pure-ADCI and mixed-ADCI/LBCI groups.
ADCI: Alzheimer’s disease-related cognitive impairment, CI: confidence interval, HL: hearing loss, LBCI: Lewy-body disease-related cognitive impair-
ment, OR: odds ratio, PTA: pure-tone average, WMHs: white-matter hyperintensities, WRS: word recognition score.
Table 2. Association of clinical factors and diagnosis with the degree of hearing impairment
PTA WRS
Model 1 p Model 2 p Model 1 p Model 2 p
Age 0.83 [0.23] <0.001* 0.83 [0.23] <0.001* -0.57 [0.31] 0.068 -0.54 [0.31] 0.083
Sex, male 5.38 [3.07] 0.083 5.44 [3.11] 0.083 -6.03 [4.37] 0.171 -6.82 [4.38] 0.123
Education level -0.22 [0.32] 0.493 -0.21 [0.32] 0.518 0.15 [0.42] 0.717 0.15 [0.42] 0.713
CMBs -0.73 [0.32] 0.023 -0.79 [0.32] 0.015*
BDI score -0.43 [0.21] 0.039 -0.43 [0.21] 0.041*
K-MMSE score 0.52 [0.34] 0.127 0.49 [0.34] 0.152
APOE4 positivity -2.24 [3.30] 0.500 -2.14 [3.31] 0.519
ADCI diagnosis -9.92 [3.24] 0.003* 11.39 [3.94] 0.005
LBCI diagnosis -0.13 [3.28] 0.968 -2.89 [4.56] 0.528
Disease group
Pure ADCI -9.03 [4.24] 0.036* 12.08 [5.82] 0.041*
Pure LBCI Reference Reference
Mixed ADCI/LBCI -10.76 [3.66] 0.004 14.61 [4.48] 0.002
Non-ADCI/LBCI -1.12 [5.18] 0.829 11.16 [7.36] 0.133
Data are beta [SE] values. Data are results of general linear models for hearing indices using age, sex, education level, and factors that showed signifi-
cant associations with hearing indices in Supplementary Table 1 as covariates. Model 1 used the presence of ADCI and LBCI as predictors. Model 2 
used disease group as a predictor. Adjusted R2 values for PTA model 1, PTA model 2, WRS model 1, and WRS model 2 were 0.267, 0.261, 0.199, and 
0.208, respectively. 
*p<0.05.
ADCI: Alzheimer’s disease-related cognitive impairment, APOE4: apolipoprotein E gene E4 variant, BDI: Beck Depression Inventory, CMB: cerebral mi-
crobleed, K-MMSE: Korean version of the Mini Mental State Examination, LBCI: Lewy-body disease-related cognitive impairment, PTA: pure-tone av-
erage, WRS: word recognition score.
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based HL between the four disease groups.
Predictors of the presence of comprehension 
dysfunction
Univariate logistic regression analyses of the presence of com-
prehension dysfunction after controlling for age, sex, and ed-
ucation level showed that periventricular WMHs, K-MMSE 
score, PTA, WRS, the presence of LBCI, and disease group 
were significantly associated with comprehension dysfunc-
tion (Supplementary Table 3 in the online-only Data Supple-
ment). Multivariate logistic regression analyses showed that 
more-severe periventricular WMHs, lower K-MMSE score, 
and higher PTA were independently associated with higher 
ORs for comprehension dysfunction (Table 4). The original 
model obtained after controlling for age, sex, education lev-
el, periventricular WMHs, K-MMSE score, and PTA showed 
that the OR for comprehension dysfunction was higher in 
the pure-LBCI group than in the pure-ADCI group. 
A sensitivity analysis in which the PTA was removed from 
the original model showed that the OR for comprehension 
dysfunction was higher in the pure-LBCI group than in the 
pure-ADCI and mixed-ADCI/LBCI groups. This sensitivity 
result indicated that given the same level of general cognition, 
patients with pure LBCI had worse comprehension func-
tion by virtue of a worse PTA compared with patients with 
mixed ADCI/LBCI. Another sensitivity analysis in which 
both the PTA and K-MMSE score were removed from the 
original model showed that the pure-LBCI group had an OR 
that was comparable with that of the mixed-ADCI/LBCI 
group, as did the original model. This sensitivity analysis in-
dicated that more-severe general cognitive dysfunction in 
the mixed-ADCI/LBCI group led to a level of comprehen-
sion dysfunction that was similar to that in the pure-LBCI 
group with a worse PTA.
DISCUSSION
This study evaluated the associations between HL and the 
mechanisms underlying CI in CI patients who were carefully 
phenotyped and diagnosed with the support of imaging bio-
markers. Our major findings are as follows: First, the pres-
ence of ADCI was associated with a lower risk of PTA-based 
HL in patients with CI or dementia. Second, the pure-LBCI 
group had a worse PTA and a higher risk of PTA-based HL 
than did the pure-ADCI and mixed-ADCI/LBCI groups. 
Third, the risk of comprehension dysfunction was higher in 
the pure-LBCI group than in the pure-ADCI group, indepen-
dent of the PTA and K-MMSE score. In addition, the pure-
LBCI group even had a higher risk of comprehension dys-
function than did the mixed-ADCI/LBCI group given the 
same level of cognition, which was attributable to worse pe-
ripheral hearing. 
Taken together, these findings indicate that ADCI is char-
acterized by relative sparing of peripheral hearing function 
and comprehension function, whereas pure LBCI is associ-
ated with an increased risk of peripheral HL (based on the 
PTA) and comprehension dysfunction. Mixed ADCI/LBCI 
shows profound cognitive dysfunction, which is further asso-
ciated with comprehension dysfunction without an increased 
risk of peripheral HL.
The absence of ADCI was associated with a higher PTA, 
lower WRS, and higher risks of PTA- and WRS-based HL 
Table 4. Association of clinical factors and diagnosis with the presence of comprehension dysfunction
Original model p Model without PTA p
Model without PTA 
and K-MMSE score
p
Age 0.97 (0.85–1.09) 0.587 1.04 (0.94–1.15) 0.468 1.08 (0.99–1.19) 0.096
Sex, male 1.46 (0.36–5.94) 0.598 2.06 (0.57–7.40) 0.269 2.53 (0.77–8.37) 0.127
Education level 0.85 (0.72–0.99) 0.042* 0.87 (0.75–1.00) 0.057 0.79 (0.69–0.91) 0.001*
Periventricular WMHs 2.90 (1.18–7.14) 0.020* 2.42 (1.06–5.55) 0.037* 2.49 (1.15–5.40) 0.021*
K-MMSE score 0.73 (0.59–0.89) 0.002* 0.77 (0.65–0.92) 0.004*
PTA 1.07 (1.02–1.12) 0.006*
Disease group
Pure ADCI 0.04 (0.003–0.490) 0.013* 0.04 (0.004–0.480) 0.010* 0.06 (0.01–0.60) 0.016*
Pure LBCI Reference Reference Reference
Mixed ADCI/LBCI 0.36 (0.09–1.55) 0.171 0.23 (0.06–0.90) 0.034* 0.50 (0.17–1.51) 0.223
Non-ADCI/LBCI 0.10 (0.01–1.29) 0.078 0.15 (0.01–1.56) 0.112 0.14 (0.02–1.07) 0.059
Data are OR (95% CI) values. Results are based on logistic regression analyses of the presence of comprehension dysfunction using age, sex, and edu-
cation level as covariates. Predictors included disease group, PTA, and K-MMSE score as appropriate. p values in the Hosmer and Lemeshow test for 
the original model, model without PTA, and model without PTA and K-MMSE score were 0.524, 0.246, and 0.342, respectively. 
*p<0.05.
ADCI: Alzheimer’s disease-related cognitive impairment, LBCI: Lewy-body disease-related cognitive impairment, OR: odds ratio, PTA: pure-tone average.
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among the enrolled patients with CI. Considering the high 
sensitivity and specificity of FBB PET in detecting histopa-
thology-confirmed β-amyloid plaques, the absence of ADCI 
in the patients with CI suggests the presence of other major 
causes of CI such as LBD and vascular disease.21,24-27 However, 
the presence of LBCI by itself was not correlated with the se-
verity and presence of HL. This could be because our study 
did not include control subjects with normal cognition and 
hearing function, which could have led to underestimation 
of the relationship between the cause of CI and HL. However, 
the pure-LBCI group had a significantly higher OR for HL 
based on the PTA than did the pure-ADCI and mixed-AD-
CI/LBCI groups. The non-ADCI/LBCI group—which had 
the most-severe vascular MRI markers (Table 1)—also had 
a higher OR for HL based on the PTA than did the pure-
ADCI and mixed-ADCI/LBCI groups (Table 3). Therefore, 
our findings suggest that LBCI without β-amyloid deposi-
tion and severe small-vessel disease as detected in brain MRI 
are associated with peripheral HL, but not with the presence 
of β-amyloid deposition on amyloid PET. This point of view 
is consistent with a recent meta-analysis not finding a signifi-
cant association between age-related HL and cognitive dys-
function in AD.28 However, since we did not recruit patholog-
ically confirmed patients and we did not evaluate the dose-
dependent relationship between β-amyloid deposition and 
HL, future studies are warranted to validate this interpretation.
Our results regarding the association between peripheral 
HL (based on the PTA) and pure LBCI are consistent with 
previous studies showing that patients with PD have periph-
eral HL.29,30 A previous study suggested that α-synuclein lo-
cated in the cochlea and stria vascularis31 is related to and 
plays a role in susceptibility to noise-induced peripheral HL.29 
Another study found that cochlear function was restored af-
ter dopamine treatment, and suggested that the depletion of 
dopamine in the olivocochlear system could expose primary 
auditory neurons to excessive glutamate release from inner 
hair cells that results in peripheral HL.30 Future studies of the 
correlation between the severities of nigrostriatal dopamine 
depletion and HL are warranted to determine if there is fur-
ther support for this hypothesis. 
Both the PTA and WRS were better in the mixed-ADCI/
LBCI group than in the pure-LBCI group. This suggests that 
the presence of LBCI does not directly indicate an increased 
risk of peripheral HL, and that there is a heterogeneity of LBCI 
in terms of HL according to the presence of ADCI. The dif-
ferential diagnosis of DLB and PD dementia is based on an 
arbitrary distinction regarding the timing of cognitive symp-
toms relative to motor symptoms.32 Considering that signifi-
cant cerebral β-amyloid deposition is more likely in patients 
with DLB than in those with PD dementia,33-35 and the het-
erogeneity in terms of HL in patients with LBCI is strongly 
correlated with the presence of concomitant β-amyloid de-
position, the phenotypical heterogeneity in LBD could be at-
tributable to these β-amyloid deposits. Future clinicopatho-
logical correlation studies and longitudinal follow-up studies 
are needed, but it is plausible that significant β-amyloid de-
position leads to more-rapid cognitive decline that prevents 
the appearance of HL in LBCI patients.
Meanwhile, it is noteworthy that the risk of PTA-based 
HL differed significantly between the study disease groups, 
whereas that of WRS-based HL did not. Pure-tone audiom-
etry measures the auditory threshold when detecting pure 
tones, while the word recognition test evaluates speech per-
ception and repetition ability. Because pure-tone audiome-
try is solely dependent on the function of cochlea and the 
neurons connected directly to the primary auditory cortex, 
it closely reflects the functioning of the peripheral auditory 
system and neural connectivity related to the primary audi-
tory cortex, with rare exceptions such as in auditory agno-
sia.36 In contrast, the WRS is affected in a complex manner 
by the brain functions of the auditory association cortex that 
involve language comprehension and expression.37 There-
fore, PTA-based HL reflects relatively peripheral HL, where-
as WRS-based HL reflects more-varied and multifactorial 
causes. Although the subjects with ADCI experienced sub-
jective hearing difficulties in our study, they exhibited supe-
rior auditory function in both pure-tone audiometry and 
the word recognition tests. This suggests that the subjective 
hearing difficulty in the ADCI group could not be explained 
by impaired auditory function, and instead was attributable 
to cognitive dysfunction in learning and memory.
Our analyses of comprehension dysfunction showed that 
auditory dysfunction was reflected in a higher PTA, cogni-
tive dysfunction was reflected in lower K-MMSE score, and 
more-severe periventricular WMHs independently contrib-
uted to comprehension dysfunction. The risk of comprehen-
sion dysfunction was higher in the pure-LBCI group than 
in the pure-ADCI group, independent of the PTA and K-
MMSE score. Given the same level of cognitive function (i.e., 
K-MMSE score), the risk of comprehension was higher in 
the pure-LBCI group than in the mixed-ADCI/LBCI group. 
These results suggest that the mixed-ADCI/LBCI group had 
better auditory function but worse general cognitive func-
tion, which led to comprehension dysfunction comparable 
to that in the pure-LBCI group. Considering our previous 
finding that patients with mixed ADCI/LBCI have additional 
cortical thinning in the bilateral temporoparietal junction and 
parietal cortices compared with patients with pure ADCI 
or pure LBCI,21 more-severe neurodegeneration involving 
the higher order auditory association cortex could explain 
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the comprehension dysfunction found in the present mixed-
ADCI/LBCI group.
This study was subject to several limitations. First, because 
the study had a cross-sectional design, the causal relationship 
between HL and CI is not yet clear. Second, the absence of a 
control group meant that our analyses could have underes-
timated the strength of the relationship between CI and HL. 
Third, although FDG PET and FBB PET were performed in 
all participants, about 10% of the LBCI patients did not un-
dergo FP-CIT PET. However, all of these patients satisfied 
the clinical criteria for DLB and had supportive findings on 
FDG PET. Fourth, although we excluded patients who were 
diagnosed as frontotemporal lobar degeneration and atypi-
cal parkinsonism including progressive supranuclear palsy, 
multiple-system atrophy, and corticobasal degeneration, it 
is possible that other pathologies such as limbic-predomi-
nant age-related TDP-43 encephalopathy or argyrophilic 
grain disease were included. Fifth, considering the low diag-
nostic sensitivity of FP-CIT imaging, there was a possibility 
of underdetection of subclinical LBD,38 since some of the pa-
tients classified into pure ADCI or non-ADCI/LBCI could 
have had subclinical LBD. Sixth, the smallness of the sample 
in the non-ADCI/LBCI group could have resulted in under-
estimation of differences in hearing impairment. Lastly, all 
patients were recruited from a university-based memory clin-
ic, which might limit the generalizability of our results. Not-
withstanding the above limitations, this is the first study to 
have investigated the relationship between CI and HL by con-
sidering the mechanisms underlying CI with imaging-bio-
marker support.
In summary, peripheral HL could be associated the absence 
of significant β-amyloid deposition in patients with CI. Pe-
ripheral HL occurred most frequently in the pure-LBCI group, 
whereas severe general cognitive dysfunction predominat-
ed in the mixed-ADCI/LBCI group, and both could lead to 
comprehension dysfunction. Our results support the com-
mon-cause hypothesis, because the mechanisms underlying 
CI affected the degree of HL given the same degree of cog-
nitive dysfunction. If the cognitive-load hypothesis or cas-
cade hypothesis were valid, the degree of HL would not have 
differed with the mechanisms underlying CI. 
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